Trazodone, a small molecule drug that selectively inhibits the serotonin reuptake transporter 5, has been an essential treatment option for depression and related disorders since its approval in December 1981 by Angelini Pharma, Inc. In addition to its antidepressant properties, trazodone is also indicated for the management of diabetic neuropathies, sleep initiation and maintenance disorders, and premature ejaculation. Its mechanism of action involves enhancing the level of serotonin in the brain, which regulates mood, appetite, and sleep patterns. Although generally well-tolerated, trazodone may cause certain adverse effects such as dizziness, dry mouth, and gastrointestinal discomfort in some patients. Click on the image below to begin the exploration journey of Trazodone through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!